PXS-5505 (pan-LOX/LOXL inhibitor)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-09-01 — Fibrocytes drive JAK2V617F-mutated myelofibrosis: pitavastatin reverses marrow fibrosis and anemia.: cross-connection with pitavastatin-mpn-fibrosis: Both are antifibrotic strategies targeting the collagen-producing compartment in MF marrow (fibrocyte inhibition vs pan-LOX/LOXL cross-linking inhibition); potential complementary mechanisms. (novelty: 4)
Open questions
Related
Contributing findings
Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis
04-aug-2026
novelty 2
per-area 3
introduces